Horizon Therapeutics plc: New Analysis Finds UPLIZNA (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)

-- Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation

Related Keywords

United States ,Ireland ,American ,Kristina Patterson ,Neuroimmunol Neuroinflamm ,Tina Ventura ,Bruce Cree ,Ray Gordon ,Rachel Vann ,Instagram ,Product Communications ,Linkedin ,Twitter ,Nasdaq ,Exchange Commission ,American Academy Of Neurology ,Facebook ,American Academy ,Seattle April ,Expanded Disability Status Scale ,California San Francisco Weill Institute ,Neuromyelitis Optica Spectrum Disorder ,Progressive Multifocal Leukoencephalopathy ,Prescribing Information ,United States Securities ,Accessed April ,Scler Relat ,Vice President ,Chief Investor Relations Officer ,Media Contact ,Horizon ,Herapeutics ,Analysis ,Kinds ,Plizna ,Inebilizumab ,Don ,Ffective ,People ,Ewly ,Resenting ,Euromyelitis ,Voptica ,Spectrum ,Disorder ,Nmosd ,